



PHARMA®
RESEARCH

PRESS RELEASE

CT Pharma Research Celebrates EPO Patent Approval for Innovative Custom Supplements® Curcumin + Selenium Orodispersible Tablet Food Supplement

[Turkiye, 03 October 2023]

CT Pharma Research, a leading pharmaceutical research and development company, is pleased to announce a significant milestone in its journey the EPO Patent Approval for Innovative Custom Supplements® Curcumin + Selenium Orodispersible Tablet Food Supplement.

The story began in 2017 when CT Pharma Research established TFL Pharma Turkiye and TFL Pharma Belgium to market and distribute developed special food supplements under the brand name "Custom Supplements®". These supplements are meticulously developed to support human health by precisely targeting the body's natural antioxidant defense system.

The European Patent Office (EPO) has granted a patent for the revolutionary formulation of "Custom Supplements® Curcumin+Selenium Orodispersible Tablet Food Supplement," a testament to CT Pharma Research's dedication to supporting the body's natural antioxidant defense system. The newly patented product seamlessly combines 45 mg of curcuminoid and 37.5 mg of curcumin's active ingredients with 10 micrograms of selenium, providing consumers with a potent and highly effective wellness solution.

Curcumin, a natural compound found in turmeric, has gained widespread recognition for its potential health benefits, including its powerful anti-inflammatory and antioxidant properties. Selenium, on the other hand, is an essential trace mineral known to support the immune system and overall health.

The orodispersible tablet form of Custom Supplements® Curcumin+Selenium offers several advantages over traditional supplement formats. Through this innovative technology, absorption begins in the mouth, ensuring enhanced bioavailability and rapid efficacy. This advancement represents a leap forward in supplement delivery methods and, ensuring that consumers receive the maximum benefits from these key ingredients.

The recent approval of the patent by the European Patent Office is a recognition of the visionary approach taken by CT Pharma Research in the field of dietary supplements. It grants our sister company TFL Pharma exclusive rights to produce and market this groundbreaking product within the EPO's jurisdiction.

"This EPO patent approval marks a significant achievement for CT Pharma Research and reaffirms our commitment to improving human health through innovative dietary supplements," said CEO, Pharmaceutical Biotechnologist Şerhan Şimşek, PhD. "Our Custom Supplements® Curcumin+Selenium Orodispersible Tablet Food Supplement showcases our unwavering dedication to providing consumers with products that are not only effective but also convenient and user-friendly."

For more information about Custom Supplements® Curcumin+Selenium Orodispersible Tablet Food Supplement and CT Pharma Research's groundbreaking initiatives, please visit www.ctpharma.com.tr

About CT Pharma Research

CT Pharma Research was established in 2012 under the name of "Custom-Tailored Pharma Research" with the aim of Custom-Tailored pharmaceutical research and development for the needs of the pharmaceutical industry.

Contact:

Şerhan Şimşek, PhD Co-Founder-CEO
Chem. Eng. Semra Aktaş Şimşek, Co-Founder-Scientific Division Director

CT Pharma Research
Phone: +90 262 642 04 21
Email: info@ctpharma.com.tr
Website: www.ctpharma.com.tr

